1Loong HH, Goto K, Solomon BJ, et al. Randomized phase III study of first-line selpercatinib versus pembrolizumab and chemotherapy in RET fusion-positive NSCLC. Abstract presented at: 48th Annual Meeting of the European Society for Medical Oncology (ESMO); October 21 2023; Madrid Spain. Accessed October 21, 2023. https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/presentation/list?q=Herbert+Loong&r=st~3
2Zhou C, Solomon BJ, Loong K, et al; LIBRETTO-431 Trial Investigators. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC. N Engl J Med. 2023;389(20):1839-1850. https://www.nejm.org/doi/10.1056/NEJMoa2309457
3Datos de archivo, Eli Lilly and Company y/o uno de sus subsidiarios.
4A study of selpercatinib (LY3527723) in participants with advanced or metastatic RET fusion-positive non-small cell lung cancer (LIBRETTO-431). ClinicalTrials.gov identifer: NCT04194944. Updated October 30, 2023. Accessed November 3, 2023. https://www.clinicaltrials.gov/ct2/show/NCT04194944
5Loong HHF, Goto K, Elamin Y, et al. LIBRETTO-431: selpercatinib in treatment (TX)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Ann Oncol. 2020;31(suppl 34):S893. European Society for Medical Oncology abstract 1413TiP. https://doi.org/10.1016/j.annonc.2020.08.1727
6Solomon BJ, Zhou CC, Drilon A, et al. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol. 2021;17(7):763-773. https://doi.org/10.2217/fon-2020-0935